SG11201903344XA - Non-human animals having an engineered immunoglobulin lambda light chain locus - Google Patents

Non-human animals having an engineered immunoglobulin lambda light chain locus

Info

Publication number
SG11201903344XA
SG11201903344XA SG11201903344XA SG11201903344XA SG11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA SG 11201903344X A SG11201903344X A SG 11201903344XA
Authority
SG
Singapore
Prior art keywords
rover
road
tarrytown
saw mill
human
Prior art date
Application number
SG11201903344XA
Other languages
English (en)
Inventor
Chunguang Guo
Faith Harris
Vera Voronina
John Mcwhirter
Natasha Levenkova
Lynn Macdonald
Naxin Tu
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201903344XA publication Critical patent/SG11201903344XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201903344XA 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus SG11201903344XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04
PCT/US2017/060006 WO2018128691A1 (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Publications (1)

Publication Number Publication Date
SG11201903344XA true SG11201903344XA (en) 2019-05-30

Family

ID=62025924

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903344XA SG11201903344XA (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus
SG10201913483XA SG10201913483XA (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913483XA SG10201913483XA (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Country Status (26)

Country Link
US (2) US10820582B2 (enrdf_load_stackoverflow)
EP (4) EP3766343B1 (enrdf_load_stackoverflow)
JP (4) JP6884860B2 (enrdf_load_stackoverflow)
KR (4) KR102658529B1 (enrdf_load_stackoverflow)
CN (2) CN114369157A (enrdf_load_stackoverflow)
AU (2) AU2017391167B2 (enrdf_load_stackoverflow)
BR (1) BR112019008675A2 (enrdf_load_stackoverflow)
CA (1) CA3038720A1 (enrdf_load_stackoverflow)
CY (2) CY1123491T1 (enrdf_load_stackoverflow)
DK (3) DK3407709T3 (enrdf_load_stackoverflow)
ES (3) ES2823305T3 (enrdf_load_stackoverflow)
FI (1) FI4082334T3 (enrdf_load_stackoverflow)
HR (3) HRP20250695T1 (enrdf_load_stackoverflow)
HU (2) HUE061980T2 (enrdf_load_stackoverflow)
IL (2) IL266282B2 (enrdf_load_stackoverflow)
LT (3) LT4082334T (enrdf_load_stackoverflow)
MA (2) MA44091A (enrdf_load_stackoverflow)
MX (2) MX385857B (enrdf_load_stackoverflow)
PL (3) PL4082334T3 (enrdf_load_stackoverflow)
PT (3) PT3766343T (enrdf_load_stackoverflow)
RS (3) RS60886B1 (enrdf_load_stackoverflow)
RU (2) RU2757665C2 (enrdf_load_stackoverflow)
SG (2) SG11201903344XA (enrdf_load_stackoverflow)
SI (3) SI4082334T1 (enrdf_load_stackoverflow)
SM (3) SMT202000558T1 (enrdf_load_stackoverflow)
WO (1) WO2018128691A1 (enrdf_load_stackoverflow)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018610A2 (en) 2010-07-26 2012-02-09 Trianni, Inc. Transgenic animals and methods of use
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
CN114369157A (zh) 2016-11-04 2022-04-19 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
IL277353B2 (en) 2018-03-24 2025-05-01 Regeneron Pharma Non-human animals genetically modified to produce therapeutic antibodies against peptide-MHC complexes, methods for their preparation and uses thereof
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
MX2021009855A (es) 2019-02-22 2021-09-10 Regeneron Pharma Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
CN114554841B (zh) * 2019-07-01 2024-06-11 特里安尼公司 转基因哺乳动物及其使用方法
EP4158034A4 (en) * 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2847885C (en) 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes
AU2004257292A1 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
WO2007143168A2 (en) 2006-06-02 2007-12-13 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
CA3038954A1 (en) 2008-09-30 2010-04-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
DK2792236T4 (da) * 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
PL2480676T3 (pl) 2010-06-22 2016-10-31 Mysz wykazująca ekspresję hybrydowego łańcucha lekkiego immunoglobuliny
HUE062552T2 (hu) 2011-02-25 2023-11-28 Regeneron Pharma ADAM6 egerek
RU2743589C2 (ru) 2011-10-17 2021-02-20 Регенерон Фармасьютикалс, Инк. Мыши с ограниченной тяжелой цепью иммуноглобулина
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
TR201903439T4 (tr) * 2011-12-20 2019-04-22 Regeneron Pharma İnsanlaştırılmış hafif zincirli fareler.
MY178882A (en) * 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
US9788534B2 (en) * 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
SG10201802295XA (en) * 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
MX385689B (es) 2014-06-06 2025-03-18 Regeneron Pharma Métodos y composiciones para modificar un locus dirigido.
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
SG10201913829YA (en) 2014-11-21 2020-03-30 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
CA2971213C (en) 2014-12-19 2023-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
CN114369157A (zh) 2016-11-04 2022-04-19 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物

Also Published As

Publication number Publication date
AU2017391167A1 (en) 2019-05-30
PT4082334T (pt) 2025-05-21
ES2823305T3 (es) 2021-05-06
IL308197A (en) 2024-01-01
JP2021090455A (ja) 2021-06-17
KR20230020550A (ko) 2023-02-10
EP3407709A1 (en) 2018-12-05
WO2018128691A1 (en) 2018-07-12
CY1125474T1 (el) 2025-05-09
SI3766343T1 (sl) 2022-06-30
ES2915609T3 (es) 2022-06-23
PT3407709T (pt) 2020-08-20
FI4082334T3 (fi) 2025-06-10
RU2019112589A3 (enrdf_load_stackoverflow) 2021-03-30
JP2023053400A (ja) 2023-04-12
JP6884860B2 (ja) 2021-06-09
CN114369157A (zh) 2022-04-19
IL266282A (en) 2019-06-30
HRP20201403T1 (hr) 2020-11-27
CN109996441B (zh) 2022-02-08
NZ753456A (en) 2021-08-27
BR112019008675A2 (pt) 2019-07-09
RS63390B1 (sr) 2022-08-31
SI3407709T1 (sl) 2020-10-30
EP3407709B9 (en) 2021-10-06
PT3766343T (pt) 2022-05-30
MX385857B (es) 2025-03-18
JP2020501516A (ja) 2020-01-23
EP4567119A2 (en) 2025-06-11
US20180125043A1 (en) 2018-05-10
EP3766343B1 (en) 2022-05-11
KR20210134059A (ko) 2021-11-08
EP3407709B1 (en) 2020-07-29
CY1123491T1 (el) 2022-03-24
JP7386292B2 (ja) 2023-11-24
AU2017391167B2 (en) 2024-02-15
MX2021010556A (es) 2021-10-01
WO2018128691A8 (en) 2019-02-28
KR102492433B1 (ko) 2023-01-30
HUE052087T2 (hu) 2021-04-28
US20210029978A1 (en) 2021-02-04
RU2757665C2 (ru) 2021-10-20
MA53935A (fr) 2021-12-22
IL266282B2 (en) 2024-04-01
SMT202000558T1 (it) 2020-11-10
AU2024200582A1 (en) 2024-03-28
RS60886B1 (sr) 2020-11-30
MA44091A (fr) 2018-10-24
HRP20250695T1 (hr) 2025-08-01
DK3407709T3 (da) 2020-08-31
MX2019005256A (es) 2019-08-05
LT4082334T (lt) 2025-05-26
US10820582B2 (en) 2020-11-03
PL4082334T3 (pl) 2025-08-11
SI4082334T1 (sl) 2025-06-30
PL3766343T3 (pl) 2022-09-26
JP2022130725A (ja) 2022-09-06
RU2019112589A (ru) 2020-12-04
LT3766343T (lt) 2022-06-10
KR20240055863A (ko) 2024-04-29
RU2021129958A (ru) 2021-11-02
CN109996441A (zh) 2019-07-09
ES3035365T3 (en) 2025-09-02
KR102319069B1 (ko) 2021-11-01
IL266282B1 (en) 2023-12-01
KR20190076024A (ko) 2019-07-01
SMT202200259T1 (it) 2022-07-21
EP4082334B1 (en) 2025-03-26
KR102658529B1 (ko) 2024-04-19
CA3038720A1 (en) 2018-07-12
RS66884B1 (sr) 2025-07-31
DK4082334T3 (da) 2025-06-02
LT3407709T (lt) 2020-10-12
SMT202500204T1 (it) 2025-07-22
HRP20220888T1 (hr) 2022-10-28
SG10201913483XA (en) 2020-03-30
HUE061980T2 (hu) 2023-09-28
DK3766343T3 (da) 2022-06-20
PL3407709T3 (pl) 2021-01-11
EP4082334A1 (en) 2022-11-02
EP3766343A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
SG11201903344XA (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201407370QA (en) Humanized il-7 rodents
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201909203WA (en) Tissue selective transgene expression
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201407789RA (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201806176PA (en) Non-human animals having an engineered angptl8 gene